AB 2489 creates the "California Veterans’ Right to Try Act," authorizing the state Research Advisory Panel (RAP) to submit one or more investigational new drug (IND) applications for multisite human trials of psilocybin, ibogaine, or other Schedule I/II substances targeting veterans. The RAP would hold those applications as "RAP-C INDs" on behalf of the state and may, if the FDA fails to timely approve the RAP-C IND, approve state-level research projects studying those controlled substances in human subjects.
The bill is narrowly focused: studies must run at 20–30 sites across California and enroll only veterans with multiple severe or life‑threatening mental‑health conditions who were ineligible for FDA‑approved trials. Applicants must show independent peer review and institutional review board (IRB) approval, but the bill also creates an expedited internal RAP review procedure exempt from Bagley‑Keene open‑meeting requirements.
The article sunsets January 1, 2028.
At a Glance
What It Does
Authorizes the Research Advisory Panel to submit and hold state INDs for psychedelic and other Schedule I/II research and, if the FDA does not 'timely' approve those INDs, allows the panel to approve bona fide research projects studying those substances in human veterans. Sets multisite trials (20–30 sites) and requires proof of independent peer review and IRB approval.
Who It Affects
Public hospitals and research institutions that would host studies, the Research Advisory Panel and its members who will review and hold RAP‑C INDs, institutional review boards and state human‑subjects oversight bodies, and veterans diagnosed with multiple severe mental‑health conditions excluded from FDA trials.
Why It Matters
The bill creates a state‑level pathway to test psychedelic and other controlled substances with a participant pool that federal trials typically exclude, potentially producing clinical data about treatments for treatment‑resistant conditions among veterans — but it does so by shifting some regulatory and ethical responsibilities from federal to state actors and by carving out an expedited, less‑transparent review mechanism.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 2489 responds to a declared veteran mental‑health emergency by giving the California Research Advisory Panel (RAP) two discrete tools: the authority to file one or more investigational new drug (IND) applications with the FDA on behalf of the state for trials of psilocybin, ibogaine, or other Schedule I/II substances, and a conditional fallback power to approve state‑supervised human research if the FDA fails to act 'timely' on those state‑filed INDs. The bill defines the RAP‑held filings as "RAP‑C INDs" and limits studies to multisite programs conducted at between 20 and 30 sites across California.
The research this law contemplates is narrowly circumscribed by participant criteria and documentation requirements. Eligible subjects must be veterans diagnosed with two or more severe or life‑threatening mental‑health conditions and who were previously excluded from FDA‑approved trials.
Applicants must show independent peer review from established bodies (for example, NIH, DoD, Heffter, NSF, or a comparable institutional review group) and supply an IRB approval letter consistent with federal protections for human subjects; municipal or county public facilities may substitute a state committee approval in certain cases.The RAP’s internal review process is procedural: the panel chair and executive officer can assign two or more individual panel members to conduct an expedited review and approve eligible applications without a full panel vote, and those assigned members are explicitly not treated as a state body under the Bagley‑Keene Open Meeting Act for that purpose. The statute is temporary — it expressly repeals itself on January 1, 2028 — and its practical effect will hinge on how the RAP implements expedited reviews, how IRBs interpret the inclusion of veterans with complex comorbidities, and whether federal regulators respond to a state acting as IND sponsor.
The Five Things You Need to Know
The RAP will hold state INDs called "RAP‑C INDs" and may submit one or more such applications for multisite trials of psilocybin, ibogaine, or other Schedule I/II substances.
Studies authorized under the article are constrained to between 20 and 30 sites across California.
Research enrollment is limited to veterans diagnosed with two or more severe or life‑threatening mental‑health conditions who were deemed ineligible for FDA‑approved trials.
Applicants must present independent peer review by bodies such as NIH, the Department of Defense, Heffter Research Institute, NSF, or a comparable institutional review, plus an IRB approval letter; municipal/county public facilities may use the State Committee for the Protection of Human Subjects as an alternative.
The RAP may use an expedited review by assigned individual members (not covered by Bagley‑Keene for that action), and the article sunsets on January 1, 2028.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Purpose and legislative findings
This section compiles the Legislature’s findings about veteran suicide, higher rates of PTSD and comorbid conditions among veterans, and the potential of psychedelic therapies. The findings justify an urgent state response and establish the policy rationale for creating a temporary legal mechanism to study Schedule I/II compounds with veteran participants who are commonly excluded from federal trials.
Short title — California Veterans’ Right to Try Act
Designates the statute’s common name. Naming matters because it signals legislative intent — the bill frames these measures as emergency, veteran‑focused exceptions to typical research pathways rather than a permanent rewrite of drug regulation.
State authority to submit and hold INDs (RAP‑C IND)
Authorizes the Research Advisory Panel to submit one or more IND applications to the FDA on behalf of California for multisite human clinical trials of specified Schedule I/II substances and to hold those applications as RAP‑C INDs. It also specifies the studies will be conducted at between 20 and 30 sites and enroll veteran‑only participant pools, creating a state‑sponsored sponsor role usually occupied by drug developers or academic sponsors.
Fallback research approval, eligibility, and review requirements
Grants the panel conditional authority to approve bona fide human‑subject research involving Schedule I/II substances if the FDA fails to timely approve the RAP‑C IND. To qualify, studies must target veterans with two or more severe or life‑threatening mental‑health conditions who were ineligible for FDA trials. Applicants must include proof of independent peer review by specified national research bodies or a comparable institutional reviewer and present IRB approval consistent with federal human‑subjects protections; municipal or county public facilities may substitute approval from the State Committee for the Protection of Human Subjects. The provision also authorizes expedited review: the panel chair and executive officer may deputize two or more individual panel members to perform and finalize reviews outside a full public meeting, and those assigned members are not treated as a state body under Bagley‑Keene when conducting that work.
Sunset
Sets the program to expire on January 1, 2028. This limits the window for state‑held IND filings and panel approvals, which affects study planning, funding timelines, and the ability to collect longer‑term outcome data under this statute.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Veterans with complex, treatment‑resistant mental‑health conditions: The bill creates a targeted avenue to enroll veterans who were excluded from standard FDA trials, potentially granting them supervised access to experimental psychedelic therapies within a supported research context.
- Public hospitals and state research institutions: These entities gain an additional, state‑sanctioned pathway to host multisite studies on Schedule I/II compounds and may become centers for veteran‑focused clinical research.
- Researchers and the psychedelic research field: Investigators may obtain data on populations—veterans with multiple comorbidities—that federal trials typically omit, improving understanding of safety and efficacy for a clinically important subgroup.
- Families and communities of veterans: If trials generate useful clinical signals, families could see new treatment avenues for veterans suffering from PTSD, treatment‑resistant depression, substance use disorders, or traumatic brain injury.
Who Bears the Cost
- Research Advisory Panel (RAP): The panel assumes administrative, legal, and sponsor‑role burdens in filing and holding INDs, plus risks associated with approving trials that federal agencies did not endorse or for which federal approval was delayed.
- Public hospitals and research sites: Institutions must absorb compliance, staffing, facility, IRB coordination, and potentially security costs tied to conducting studies with controlled substances, including measures for safe storage, administration, and post‑treatment monitoring.
- Institutional Review Boards and oversight bodies: IRBs and the State Committee for the Protection of Human Subjects will face increased workload and reputational risk reviewing high‑risk studies involving vulnerable veteran populations.
- State of California (legal and fiscal exposure): The state could face legal challenges over federal preemption, disputes over the meaning of 'timely' FDA action, or challenges to the RAP’s expedited, nonpublic review procedures — all of which carry litigation and political costs.
Key Issues
The Core Tension
The bill trades speed and inclusion for regulatory certainty and transparency: it aims to accelerate access to experimental treatments for veterans excluded from federal trials, but doing so shifts regulatory responsibilities to state actors, introduces ambiguous triggers for state action, and compresses oversight into an expedited, less‑public review process — creating a necessary but fraught choice between urgent access and the traditional federal safety net.
The bill creates a novel state‑level research sponsor role but leaves unresolved how that role interacts with federal authority under the Controlled Substances Act, FDA regulations, and DEA enforcement. The statute conditions the RAP’s fallback approval on an undefined failure by the FDA to act 'timely' — a term that invites litigation or adversarial interpretation.
That ambiguity could produce procedural delays the law purports to avoid.
Ethically and scientifically, the statute deliberately targets a population excluded from conventional trials: veterans with multiple severe conditions. That inclusion responds to a clinical gap, but it raises questions about safety, informed consent, and the generalizability of results.
The expedited internal review path (assigned individual panel members not treated as a state body under Bagley‑Keene) speeds decisions but reduces public transparency and may undermine external confidence in oversight. Finally, the statute’s sunset (January 1, 2028) compresses timelines for recruitment and follow‑up, limiting the ability to generate robust long‑term safety and efficacy data and complicating the path to broader clinical adoption or VA coverage.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.